Minimally invasive drug delivery systems (MIDDS) have emerged as transformative tools in modern medicine, addressing the limitations of traditional administration methods such as oral and injectable routes. These innovative systems, including microneedles, nanocarriers, and implantable devices, provide targeted, efficient, and patient-friendly solutions. Technologies like 3D printing and bioresponsive materials have enhanced drug delivery precision, while digital integration supports personalized healthcare. By overcoming barriers such as poor bioavailability, systemic toxicity, and patient noncompliance, MIDDS are reshaping drug administration across various therapeutic areas, from chronic diseases to oncology. This article aims to explore the advancements in minimally invasive drug delivery systems (MIDDS), including microneedles, nanocarriers, and implantable devices, emphasizing their industrial applications and innovations for personalized healthcare solutions. The industrial perspective on MIDDS highlights its transformative role in pharmaceuticals by offering alternatives to traditional drug administration methods. Microneedle technology, combined with advances in materials science and fabrication techniques, has enabled painless and efficient drug delivery for vaccines, insulin, and cancer therapies. Nanocarriers provide targeted delivery and controlled release, enhancing efficacy while minimizing systemic toxicity. Integration with digital health tools, such as wearable devices and AI-driven systems, further supports personalized medicine and remote patient management. Continued research and cross-disciplinary collaboration are crucial to overcoming current limitations and optimizing MIDDS for clinical and industrial use. Minimally invasive drug delivery systems (MIDDS) demonstrate significant potential to improve drug administration, enhance patient compliance, and achieve targeted therapeutic outcomes. Key technologies, such as microneedles, nanocarriers, and implantable devices, have revolutionized drug delivery with innovations like 3D printing, bioresponsive systems, and digital integration. These systems offer precise control, reduced side effects, and broader applicability across various medical fields. However, challenges like manufacturing complexity, regulatory barriers, and cost must be addressed for widespread adoption.